aTYR PHARMA (ATYR) Change in Acquisitions & Divestments (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Change in Acquisitions & Divestments data on file, last reported at $17.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 6.34% year-over-year to $17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.3 million (up 2.58% YoY) and the FY2025 annual result came in at $88.5 million, up 2.39% from the prior year.
• Change in Acquisitions & Divestments retreated to $17.5 million in Q1 2026, from $29.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $33.6 million in Q3 2023 to a low of $9.3 million in Q1 2023.
• A 5-year average of $22.0 million and a median of $20.9 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 530.43% — and 2024, when it sank 37.79%.
• Tracing ATYR's Change in Acquisitions & Divestments over 5 years: stood at $28.1 million in 2022, then dropped by 2.18% to $27.5 million in 2023, then decreased by 27.27% to $20.0 million in 2024, then soared by 46.54% to $29.3 million in 2025, then slumped by 40.29% to $17.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $17.5 million (Q1 2026), $29.3 million (Q4 2025), and $19.0 million (Q3 2025), per Business Quant data.